eligibility_summary
Inclusion: consent, adults with R/R DLBCL (incl PMBCL or transformed FL), refractory to last therapy or ineligible/refractory to ASCT, ≥2 prior lines incl anthracycline, CD19+, measurable disease, survival >12 wks, ECOG 0–1, adequate renal/hepatic/pulmonary function, LVEF ≥45%, drug washouts, recovered AEs, contraception. Exclusion: CNS disease, prior allo-HSCT, recent chemo/other trials, active HBV/HCV, HIV/syphilis, uncontrolled infection, recent MI/angina, other cancers (limited exceptions), pregnancy, neuroautoimmune, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Meta10-19, a metabolically armed anti-CD19 autologous CAR-T cell therapy (gene‑modified T cells), given after lymphodepletion with cyclophosphamide (alkylating agent) and fludarabine (purine analog). Mechanism of action: CAR-T cells expressing a CD19-specific receptor recognize CD19 on B cells and trigger T‑cell activation and cytotoxic killing, the “metabolic armoring” is intended to enhance T‑cell metabolic fitness, expansion, and persistence in the tumor microenvironment (specific modifications not detailed). Targets: CD19+ malignant B cells in DLBCL, pathways include CAR signaling in T cells (activation/co‑stimulation) and host lymphodepletion to facilitate CAR‑T expansion.